rucaparib
rucaparib: 16 clinical trials tracked.
rucaparib evidence translation
What we can confirm
16 tracked trials
What it means
What to watch
Prepared research question
What is verified about rucaparib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Clinical Trials (16)showing 10 most recent
Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma
Primary endpoint: Best Objective Response Rate
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Primary endpoint: Number of Participants With Relevant Co-morbidities
A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Primary endpoint: Maximum Tolerated Dose
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Primary endpoint: Incidence of Adverse Events (AEs)
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Primary endpoint: Treatment Related Overall Response Rate
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Primary endpoint: Progression Free Survival (PFS)
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
Primary endpoint: Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma
Primary endpoint: Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab
Primary endpoint: Median Duration of Time From Start of Treatment to Time of Progression
A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy
Primary endpoint: Dose Limiting Toxicities